Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 06:11:03 18/06/2024 pm IST			5-day change	1st Jan Change
246.4 ^CHF	+0.35%		+2.11%	+0.90%

01:00pm	Roche partners with Ascidian Therapeutics to develop gene therapies	RE
11:52am	Roche: approval for digital pathology system	CF

ROCHE HOLDINGS AG : Goldman Sachs remains a Sell rating

May 30, 2024 at 11:34 am IST

Goldman Sachs's analyst James Quigley maintains his Sell rating on the stock.

Latest news about Roche Holding AG

Roche partners with Ascidian Therapeutics to develop gene therapies	04:30pm	RE
Roche: approval for digital pathology system	03:22pm	CF
ROCHE HOLDINGS AG : Goldman Sachs gives a Sell rating	17/06	ZD
ROCHE HOLDINGS AG : Deutsche Bank sticks Neutral	17/06	ZD
ROCHE HOLDINGS AG : Gets a Neutral rating from Barclays	17/06	ZD
ROCHE HOLDINGS AG : JP Morgan gives a Sell rating	17/06	ZD
Roche: positive phase III data in lymphoma	17/06	CF
Roche's Blood Cancer Combo Reduces Risk of Death in Late-stage Study	17/06	MT
Transcript : Roche Holding AG - Shareholder/Analyst Call	16/06
Roche?s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma	15/06	CI
Roche: collaboration agreement in colon cancer	14/06	CF
Nkarta, Inc. Appoints George Vratsanos as Board of Directors	14/06	CI
AbbVie inks immune disorder drug licensing deal with China's FutureGen	13/06	RE
Swiss Stocks Flash Red as US Fed Decision Takes Spotlight	10/06	MT
Global markets live: ABB, Roche, Microsoft, Apple, Tesla...	10/06
Roche's Lung Cancer Drug Notches EU Win After 'Unprecedented' Late-stage Study Results	10/06	MT
Roche: FDA clearance for virus test	10/06	CF
Roche: EU approval for lung cancer	10/06	CF
Roche Secures EU Approval for Early-Stage Lung Cancer Treatment	10/06	MT
Roche Obtains US FDA Emergency Use Permit for Four-in-one Molecular Test	10/06	MT
European Commission Approves Roche's Alecensa as the First and Only Targeted Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer	10/06	CI
Roche: efficacy of Evrysdi in spinal muscular atrophy	07/06	CF
Roche's Five-year Data Confirms Efficacy, Safety of Evrysdi Drug for Spinal Muscular Atrophy in Children	07/06	MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	07/06	MT
AlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Buy Recommendation	06/06	MT

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

12:30pm - Citi European Healthcare Conference

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 09:20 pm IST

Obesity: Roche joins the battle

December 04, 2023 at 09:18 pm IST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

245.5 CHF

Average target price

278.1 CHF

Spread / Average Target

+13.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	+0.90%	22TCr
ELI LILLY AND COMPANY	+51.82%	80TCr
NOVO NORDISK A/S	+40.58%	63TCr
JOHNSON & JOHNSON	-6.88%	35TCr
MERCK & CO., INC.	+16.95%	32TCr
ABBVIE INC.	+9.49%	30TCr
ASTRAZENECA PLC	+17.04%	24TCr
AMGEN INC.	+5.30%	16TCr
PFIZER, INC.	-6.29%	15TCr
SANOFI	-2.18%	12TCr

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : Goldman Sachs remains a Sell rating

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals